Isis Calls Out Santaris Over Drug Development Deals

Law360, Los Angeles (September 23, 2011, 6:35 PM EDT) -- Drug developer Isis Pharmaceuticals Inc. slammed Santaris Pharma A/S Corp. with a patent infringement lawsuit Thursday, accusing its competitor of leveraging Isis’ patented gapmer antisense drug development platform to sign multimillion-dollar deals with drug industry giants.

“Santaris’ business has been built around exploiting the platform antisense technology pioneered and patented by Isis, and selling and offering it for sale to pharmaceutical companies ... Santaris booked millions of dollars of revenue from sales of Isis’ patented gapmer antisense technology,” it said.

The suit accuses the Danish pharmaceutical developer...
To view the full article, register now.